Denmark· DK-28105633515

OCALIVA

A obeticholic acid product containing obeticholsyre, registered in Denmark by Advanz Pharma Limited. The same ATC class is registered in 7 of our 19 countries.

ATC A05AA04

Checked against Danish Medicines Agency (Denmark) on

Informational only — not a medical device.

SOURCE REGISTER · DKDanish Medicines Agency (Denmark)normalisedOCALIVAATCA05AA04REGISTER NO.DK-28105633515PACKS LISTED1CHECKEDSeptember 30, 2026

Where it is registered

Obeticholic acid is registered in 7 of 19 countries.

Countries holding a registration under ATC A05AA04 (obeticholic acid), each read from that country’s own register.

  • This record: Denmark, from Danish Medicines Agency (Denmark)
  • 3 of them publish a price we can compare per daily dose

Obeticholic acid · ATC A05AA04

7 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Ireland
  • Norwayprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Danish Medicines Agency (Denmark)
Active substance
obeticholsyre
Manufacturer
Advanz Pharma Limited
Country
Denmark (DK)
ATC code
A05AA04
ATC class
Obeticholic acid
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
Danish Medicines Agency (Denmark)
Last checked
September 30, 2026

Packs & prices · 1

  • dk_varenummer
    28105633515

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

49 interactions on record for obeticholic acid.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Obeticholic acid · interactions on record

49 records

  • 2 severe
  • 44 moderate
  • 3 minor

Most severe, free to view

  • GrazoprevirJ05AP11severe
  • TizanidineM03BX02severe
  • AlosetronA03AE01moderate
  • DicoumarolB01AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e6e8dd41-0a41-4820-81ca-19779968a7b6
GET /v1/drugs/e6e8dd41-0a41-4820-81ca-19779968a7b6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "filmovertrukne tabletter",
  "source": "dkma",
  "strength": "10 mg",
  "auth_role": "MOD",
  "dk_drugid": "28105633515",
  "substance": "obeticholsyre",
  "auth_procedure": "Central",
  "in_medicinpriser": false,
  "registration_date_serial": "42716"
}

See everything about obeticholic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.